Ratings for IGM Biosciences (NASDAQ:IGMS) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 2 | 2 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 1 | 2 | 1 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
The 12-month price targets, analyzed by analysts, offer insights with an average target of $18.4, a high estimate of $25.00, and a low estimate of $11.00. This upward trend is apparent, with the current average reflecting a 4.55% increase from the previous average price target of $17.60.
Decoding Analyst Ratings: A Detailed Look
An in-depth analysis of recent analyst...
Login or create a forever free account to read this news
Sign up/Log in
